代謝疾患治療薬の世界市場:高血圧、肥満、高コレステロール血症、ライソゾーム病

◆英語タイトル:Global Metabolic Disorders Therapeutics Market 2016-2020
◆商品コード:IRTNTR10218
◆発行会社(調査会社):Technavio
◆発行日:2016年9月27日
◆ページ数:163
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、代謝疾患治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、代謝疾患治療薬の世界市場規模及び予測、種類別分析、市場シェア、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Metabolic Disorders
Metabolic disorders occur as a result of disruption of chemical processes and conversions occurring in the cells and fluids of the body. This is mainly because of defects in the enzyme; all process in the body are controlled by enzymes. Any disruption in the pathways involved in the development and metabolism of carbohydrates, proteins, fats, and nucleic acids, results in the development of metabolic disorders.

Technavio’s analysts forecast the global metabolic disorders therapeutics market to grow at a CAGR of 4.62% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global metabolic disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various metabolic disorders including diabetes, obesity, lysosomal storage diseases, and hypercholesterolemia.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Metabolic Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Novo Nordisk
• Sanofi
• Merck
• AstraZeneca
• Eli Lilly

[Other prominent vendors]
• AbbVie
• Actelion Pharmaceuticals
• Adocia
• Aegerion Pharmaceuticals
• Akros Pharma
• Alnylam Pharmaceuticals
• Amarin
• nAmgen
• Amicus Therapeutics
• Arbutus Biopharma
• Arena Pharmaceuticals
• Astellas Pharma
• Atheronova
• Aurobindo Pharma
• Baxalta
• Belrose Pharma
• BHV Pharma
• Biocon
• Biodel
• BioMarin
• Bionaturis
• Biosidus
• Biospherics
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Catabasis Pharmaceuticals
• Cerenis Therapeutics
• Chipscreen Biosciences
• Cipla
• CJ HealthCare
• CKD Bio
• Concord Biotech
• ConjuChem
• CureDm
• CymaBay Therapeutics
• Daewoong
• Daiichi Sankyo
• Dance Biopharm
• DiaMedica
• Diamyd Therapeutics
• Diasome Pharmaceuticals
• DiaVacs
• Dong-A ST
• Eisai
• Elcelyx Therapeutics
• Esperion Therapeutics
• Exsulin
• F. Hoffmann-La Roche
• Gan & Lee Pharmaceuticals
• Generex Biotechnology
• Genfit
• GlaxoSmithKline
• HanAll BioPharma
• Hanmi Pharmaceutical Company
• Hua Medicine
• Iltoo Pharma
• Intarcia Therapeutics
• InteKrin Therapeutics
• Intrexon
• Ionis Pharmaceuticals
• Islet Sciences
• ISU Abxis
• Janssen Pharmaceuticals
• Japan Tobacco
• JCR Pharmaceuticals
• JW Pharmaceuticals
• Kadmon Pharmaceuticals
• Kamada
• KinDex Pharmaceuticals
• Kissei
• Kotobuki
• Kowa Company
• Laboratoires SMB
• Lexicon Pharmaceuticals
• Ligand Pharmaceuticals
• Living Cell Technologies
• Livzon
• LIXTE Biotechnology
• Lupin
• MacroGenics
• Madrigal Pharmaceuticals
• MannKind
• MedImmune
• Melior Pharmaceuticals
• Merrion Pharmaceuticals
• Merz Pharmaceuticals
• Metabolic Solutions Development Company
• Mitsubishi Tanabe Pharma
• Mylan
• Neothetics
• Neuraltus Pharmaceuticals
• NGM Biopharmaceuticals
• NGM Biopharmaceuticals
• Norgine BV
• Novartis
• NuSirt Biopharma
• Oramed
• Orexigen Therapeutics
• Osiris Therapeutics
• Peptron
• Perle Biosciences
• Pfizer
• PhaseBio Pharmaceuticals
• Poxel
• Protalix Biotherapeutics
• Raptor
• Recordati
• Regeneron Pharmaceuticals
• Regeneron Pharmaceuticals
• REGiMMUNE
• Rhythm Pharmaceuticals
• Saniona
• Santaris Pharma
• Santaris Pharma
• Serometrix
• Shionogi
• Shire
• Sigma-Tau
• Sirona Biochem
• Strongbridge Biopharma
• SUN Pharma
• Takeda
• Teva
• Thera technologies
• Theracos
• Toleranzia
• Tolerion
• Torrent Pharmaceuticals
• Transition Therapeutics
• UCB
• Utrecht Holdings
• VeroScience
• Vivus
• vTv Therapeutics
• XBiotech
• Xeris Pharmaceuticals
• XOMA
• Zafgen
• Zydus Cadila

[Market driver]
• Increase in academia-industry collaborations for drug development
• For a full, detailed list, view our report

[Market challenge]
• Low compliance and adherence rates
• For a full, detailed list, view our report

[Market trend]
• Increase in academia-industry collaborations for drug development
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Pipeline portfolio
• Pipeline portfolio: Global diabetes drugs market
• Pipeline portfolio: Global hyperphosphatemia drugs market
• Pipeline portfolio: Global anti-obesity drugs market

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation by type of disease
• Diabetes
• Obesity
• Hypercholesterolemia
• Lysosomal storage diseases

PART 08: Global diabetes drugs market
• Market overview
• Global type 1 diabetes market
• Global type 2 diabetes drugs market
• Vendors in global diabetes drugs market

PART 09: Global hypercholesterolemia drugs market
• Market overview
• Vendors in global hypercholesterolemia drugs market

PART 10: Global lysosomal storage diseases market
• Market overview
• Vendors in global lysosomal storage disorders drugs market

PART 11: Global anti-obesity drugs market
• Market overview
• Vendors in global anti-obesity drugs market

PART 12: Geographical segmentation
• Global metabolic disorders therapeutics market by geography 2015-2020
• Metabolic disorders therapeutics market in Americas
• Metabolic disorders therapeutics market in EMEA
• Metabolic disorders therapeutics market in APAC

PART 13: Market drivers
• Patient assistance programs
• Special regulatory designations for rare diseases
• Increase in academia-industry collaborations for drug development

PART 14: Impact of drivers

PART 15: Market challenges
• Low compliance and adherence rates
• High cost of therapies
• Complex storage conditions and distribution policies for insulin

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Focus on oral insulin therapies
• Strong and diversified pipeline portfolio
• Strategic collaborations and acquisitions

PART 18: Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 19: Key vendor analysis
• Novo Nordisk
• Sanof
• Merck
• AstraZeneca
• Eli Lilly

PART 20: Appendix
• List of abbreviations

PART 21: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria and customer segments for metabolic disorder drugsKey buying criteria for metabolic disorders drugs 2015
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Global metabolic disorders therapeutic market snapshot: Developed and emerging markets 2015
Exhibit 05: Global metabolic disorders therapeutics market 2015-2020 ($ billions)
Exhibit 06: Opportunity analysis: Global metabolic disorders therapeutics market
Exhibit 07: Global metabolic disorders therapeutics market: Growth cycle analysis
Exhibit 08: Five forces analysis
Exhibit 09: Global metabolic disorders therapeutics market by type of disease
Exhibit 10: Global metabolic disorders therapeutics market by type (2015-2020)
Exhibit 11: Global metabolic disorders therapeutics market n growth lifecycle analysis
Exhibit 12: Top selling diabetes drugs based on sales 2015 ($ billions)
Exhibit 13: Market share of global diabetes drugs in global pharmaceutical market 2015
Exhibit 14: Global diabetes drugs market 2015-2020 ($ billions)
Exhibit 15: Global type 1 diabetes market 2015-2020 ($ billions)
Exhibit 16: Global type 2 diabetes drugs market 2015-2020 ($ billions)
Exhibit 17: Market share analysis of vendors in global diabetes drugs market
Exhibit 18: Revenues from the sales of top five products in global diabetes drugs market 2013-2015 ($ billions)
Exhibit 19: Revenues from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions)
Exhibit 20: Market dynamics of hypercholesterolemia drugs
Exhibit 21: Percentage share of hypercholesterolemia drugs by drug class 2015
Exhibit 22: Global hypercholesterolemia drugs market 2015-2020 ($ billions)
Exhibit 23: Market share analysis of global hypercholesterolemia drugs market 2015
Exhibit 24: Products offered by major vendors in global hypercholesterolemia drugs market
Exhibit 25: Global lysosomal storage diseases drugs market 2015-2020 ($ billions)
Exhibit 26: Key events in treatment of lysosomal storage diseases
Exhibit 27: Products offered by major vendors in global lysosomal storage disorders drugs market
Exhibit 28: Global anti-obesity drugs market 2015-2020 ($ millions)
Exhibit 29: Products offered by major vendors in global anti-obesity drugs market
Exhibit 30: Global metabolic disorders therapeutics market by geography 2015-2020
Exhibit 31: Global metabolic disorder therapeutics market by geography 2015 and 2020
Exhibit 32: Global metabolic disorder therapeutics market by geography 2015-2020 ($ billions)
Exhibit 33: Global share of metabolic disorder therapeutics market by geography 2015
Exhibit 34: Global share of various metabolic disorder therapeutics market by geography based on disease type 2015
Exhibit 35: Global metabolic disorders therapeutics market by region: Market growth lifecycle analysis 2015
Exhibit 36: Metabolic disorder therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 37: Prevalence of obesity in various countries in Europe 2025
Exhibit 38: Metabolic disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 39: Metabolic disorder therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 40: Prevalence of diabetes in selected countries in APAC 2007 and 2025
Exhibit 41: Few metabolic disorder drugs with patient assistance programs
Exhibit 42: Impact of drivers
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Oral insulin pipeline portfolio
Exhibit 45: Some investigational molecules for metabolic disorders and their mechanisms
Exhibit 46: Key vendors ranking 2015
Exhibit 47: Geographical presence of key vendors
Exhibit 48: Competitive scenario of global metabolic disorders therapeutics market vendors 2015-2020
Exhibit 49: Novo Nordisk: Profile
Exhibit 50: Novo Nordisk: Strength analysis
Exhibit 51: Novo Nordisk: Growth strategy matrix
Exhibit 52: Novo Nordisk: Growth opportunity assessment
Exhibit 53: Novo Nordisk: Business segmentation by revenue 2015
Exhibit 54: Novo Nordisk: Key products in diabetes and obesity care
Exhibit 55: Novo Nordisk: YoY growth and revenue generated from net product sales of human insulins 2012-2015 ($ billions)
Exhibit 56: Novo Nordisk: YoY growth and revenue generated from net product sales of Levemir 2012-2015 ($ billions)
Exhibit 57: Novo Nordisk: YoY growth and revenue of NovoRapid/ NovoLog 2012-2015 ($ billions)
Exhibit 58: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog Mix 2012-2015 ($ billions)
Exhibit 59: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions)
Exhibit 60: Novo Nordisk: YoY growth and revenue of Victoza 2012-2015 ($ billions)
Exhibit 61: Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and Prandimet 2012-2014 ($ billions)
Exhibit 62: Sanofi: Business segmentation by revenue 2015
Exhibit 63: Sanofi: Profile
Exhibit 64: Sanofi: Strength analysis
Exhibit 65: Sanofi growth strategy matrix
Exhibit 66: Sanofi: Growth opportunity assessment
Exhibit 67: Key product offerings in diabetes market ($ billions)
Exhibit 68: Sanofi: YoY revenue and growth rate of Lantus 2012-2015 ($ billions)
Exhibit 69: Sanofi: YoY revenue and growth rate of Amaryl 2012-2015 ($ billions)
Exhibit 70: Sanofi: YoY revenue and growth rate of Apidra 2012-2015 ($ billions)
Exhibit 71: Sanofi: YoY revenue and growth rate of Insuman 2012-2015 ($ billions)
Exhibit 72: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
Exhibit 73: Sanofi: Revenues of lysosomal storage diseases drugs of Genzyme, 2015
Exhibit 74: Merck: Strength profile
Exhibit 75: Merck: Strength analysis
Exhibit 76: Merck: Growth strategy matrix
Exhibit 77: Merck: Opportunity assessment
Exhibit 78: Top selling diabetes drugs in 2015
Exhibit 79: Merck: Diabetes segmentation by revenue 2015
Exhibit 80: Merck: YoY growth and revenue of Janumet 2012-2015 ($ billions)
Exhibit 81: Merck: YoY growth and revenue of Januvia 2012-2015 ($ billions)
Exhibit 82: Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions)
Exhibit 83: Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions)
Exhibit 84: Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions)
Exhibit 85: AstraZeneca: Profile
Exhibit 86: AstraZeneca: Strength analysis
Exhibit 87: AstraZeneca: Growth strategy matrix
Exhibit 88: AstraZeneca: Opportunity assessment
Exhibit 89: Top selling diabetes drugs in 2015 ($ billions)
Exhibit 90: AstraZeneca: Byetta YoY growth and revenues 2012-2015 ($ billions)
Exhibit 91: Astrazeneca: Byetta YoY growth rate and revenues in the US ($ billions)
Exhibit 92: AstraZeneca: Bydureon YoY revenues and growth rate 2012-2015 ($ billions)
Exhibit 93: AstraZeneca: Onglyza YoY revenue and growth rate 2012-2015 ($ billions)
Exhibit 94: AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions)
Exhibit 95: AstraZeneca: Geographical segmentation of Crestor 2015 by revenue
Exhibit 96: Eli Lilly: Profile
Exhibit 97: Eli Lilly: Strength analysis
Exhibit 98: Eli Lilly growth strategy matrix
Exhibit 99: Eli Lilly: Opportunity assessment
Exhibit 100: Top selling diabetic drugs 2015 ($ billions)
Exhibit 101: Eli Lilly: YoY revenue and growth rate of Humalog 2012-2015 ($ billions)
Exhibit 102: Eli Lilly: YoY revenue and growth rate of Humulin 2012-2015 ($ billions)
Exhibit 103: Eli Lilly: YoY revenue and growth rate of Tradjenta 2012-2015 ($ billions)
Exhibit 104: Eli Lilly: YoY revenue of Trylicity 2014-2015 ($ millions)



【掲載企業】

Novo Nordisk, Sanofi, Merck, AstraZeneca, and Eli Lilly.

Other Prominent Vendors in the market are: AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, nAmgen, Amicus Therapeutics, Arbutus Biopharma, Arena Pharmaceuticals, Astellas Pharma, Atheronova, Aurobindo Pharma, Baxalta, Belrose Pharma, BHV Pharma, Biocon, Biodel, BioMarin, Bionaturis, Biosidus, Biospherics, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, ConjuChem, CureDm, CymaBay Therapeutics, Daewoong, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Esperion Therapeutics, Exsulin, F. Hoffmann-La Roche, Gan & Lee Pharmaceuticals, Generex Biotechnology, Genfit, GlaxoSmithKline, HanAll BioPharma, Hanmi Pharmaceutical Company, Hua Medicine, Iltoo Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Islet Sciences, ISU Abxis, Janssen Pharmaceuticals, Japan Tobacco, JCR Pharmaceuticals, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kamada, KinDex Pharmaceuticals, Kissei, Kotobuki, Kowa Company, Laboratoires SMB, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Living Cell Technologies, Livzon, LIXTE Biotechnology, Lupin, MacroGenics, Madrigal Pharmaceuticals, MannKind, MedImmune, Melior Pharmaceuticals, Merrion Pharmaceuticals, Merz Pharmaceuticals, Metabolic Solutions Development Company, Mitsubishi Tanabe Pharma, Mylan, Neothetics, Neuraltus Pharmaceuticals, NGM Biopharmaceuticals, NGM Biopharmaceuticals, Norgine BV, Novartis, NuSirt Biopharma, Oramed, Orexigen Therapeutics, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, Protalix Biotherapeutics, Raptor, Recordati, Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, REGiMMUNE, Rhythm Pharmaceuticals, Saniona, Santaris Pharma, Santaris Pharma, Serometrix, Shionogi, Shire, Sigma-Tau, Sirona Biochem, Strongbridge Biopharma, SUN Pharma, Takeda, Teva, Thera technologies , Theracos, Toleranzia, Tolerion, Torrent Pharmaceuticals, Transition Therapeutics, UCB, Utrecht Holdings, VeroScience, Vivus, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA, Zafgen, and Zydus Cadila.

【レポートのキーワード】

代謝疾患治療薬、高血圧、肥満、高コレステロール血症、ライソゾーム病、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[代謝疾患治療薬の世界市場:高血圧、肥満、高コレステロール血症、ライソゾーム病]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月11日現在 219,328 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆